证券代码：000504 证券简称：南华生物 公告编号：2024-037 南华生物医药股份有限公司 特别提示： 1.案件所处的诉讼阶段：法院已立案受理； 2.控股子公司所处的当事人地位：原告； 3.涉案的金额：货款本金 15,235,388.74 元，违约金 8,471,487.81 元(暂计 算至 2024 年 4 月 30 日，之后按照合同约定的方式计算至实际清偿之日),以上合 计 23,706,876.55 元； 4.对上市公司损益产生的影响:本次诉讼事项尚未开庭审理，暂不会对公司 目前的经营和财务状况造成影响。本次公司之控股子公司提起诉讼系为加快其采 购款回款进度，依法保障上市公司的合法权益之举措。 一、本次诉讼事项受理的基本情况 关于控股子公司提起诉讼的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 南华生物医药股份有限公司（以下简称"公司"）控股子公司南华干细胞再 生医学临床转化研究中心有限责任公司（以下简称"南华干细胞"）就其与天富 环保生物科技（江苏）有限公司（以下简称"天富环保"）、常州科威乐健医疗 用品有限公司（以下简称"科威乐健"） ...

Financial Performance Expectations - The company expects a net loss attributable to shareholders of between 8.5 million and 10.5 million yuan for the first half of 2024, compared to a loss of 8.9732 million yuan in the same period last year [3]. - The net profit after deducting non-recurring gains and losses is projected to be a loss between 11 million and 13 million yuan, compared to a loss of 10.8470 million yuan in the previous year [3]. - The basic earnings per share is anticipated to be a loss between 0.0257 yuan and 0.0318 yuan, compared to a loss of 0.0288 yuan per share in the same period last year [3]. Revenue and Asset Management - The company's overall revenue has decreased year-on-year due to market conditions, leading to an increase in asset impairment provisions [10]. - The financial situation and capital structure have improved following the completion of a non-public offering of A shares in 2023, reducing the financial cost burden [10]. Caution and Communication - The performance forecast data is preliminary and has not been audited by registered accountants, with final figures to be disclosed in the 2024 semi-annual report [5][7]. - Investors are advised to make cautious decisions and be aware of investment risks due to the anticipated losses [5]. - The company has communicated with the accounting firm regarding the reasons for the expected losses in the first half of 2024 [10].

证券代码：000504 证券简称：南华生物 公告编号：2024-035 南华生物医药股份有限公司 关于控股孙公司之孙公司诉讼事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 一、本次诉讼事项的基本情况 南华生物医药股份有限公司（以下简称"公司"）控股孙公司城光（湖南） 节能环保服务股份有限公司（以下简称"城光公司"）之全资孙公司岷县万洁热 力有限公司（公司间接持有其权益约为 23.72%，以下简称"万洁热力"）于此 前就其与岷县宏源清洁热力有限公司（以下简称"宏源热力"）代付款等纠纷一 案向甘肃省岷县人民法院（以下简称"岷县人民法院"）提起诉讼，请求确认双 方订立的《岷县集中供热项目供热配套设施的租赁协议》《供用热合同》已解除， 请求判令宏源热力向万洁热力偿还超额代付款、其他代付款及相关利息，并承担 本案全部诉讼费用、保全费、保全保险费。后宏源热力就相关事项提起反诉，请 求由万洁热力分担 2021 年至 2022 年供暖期因煤价飙涨造成宏源热力亏损，并请 求由万洁热力全部承担诉讼费用及其他诉讼费；2023 年 7 月，公司收到城光公 司转来的《 ...

证券代码：000504 证券简称：南华生物 公告编号：2024-034 南华生物医药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动的情况介绍 南华生物医药股份有限公司（以下简称"公司"或"南华生物"）股票（证 券简称：南华生物，证券代码：000504）于2024年6月20日、2024年6月21日连续 两个交易日内收盘价格涨幅偏离值累计超过20%，根据《深圳证券交易所交易规 则》的有关规定，属于股票异常波动情形。 二、公司关注并核实情况 （一）公司核查情况 6.本公司不存在需要根据深交所《股票上市规则》等有关规定应予以披露而 未披露的、对本公司股票及其衍生品种交易价格产生较大影响的信息、重大风险 事项和其他可能导致股票交易异常波动的事项。 （二）公司控股股东核查情况 1 公司控股股东湖南省财信产业基金管理有限公司（以下简称"财信产业基 金"）、公司间接控股股东湖南财信金融控股集团有限公司（以下简称"财信金 控"）就公司股票异常波动相关事宜进行了核查，情况说明如下： 1.目前不存在关于南华生物应披露未披露 ...

湖南湘军麓和律师事务所 关于南华生物医药股份有限公司 2023 年年度股东大会的 湖南湘军麓和律师事务所 2023 年年度股东大会法律意见书 湖南湘军麓和律师事务所 关于南华生物医药股份有限公司 2023 年年度股东大会的法律意见书 致：南华生物医药股份有限公司 法律意见书 湖南湘军麓和律师事务所 HUNAN XIANGJUNLUHE LAW FIRM 二○二四年五月 地址：湖南省长沙市芙蓉区远大一路 280 号湘域相遇 B 座 4 楼、8 楼及 C 座 4 楼 联系电话：(0731) 84587101 / 84587102 网址：www.xjlhlawyer.com 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）和中国证券监督管理委员会发布的《上市公司 股东大会规则》（以下简称"《股东大会规则》"）、《深圳证券交易所上市公司股东 大会网络投票实施细则》（以下简称"《网络投票实施细则》"）等有关规定，湖南 湘军麓和律师事务所（以下简称"本所"）接受南华生物医药股份有限公司（以 下简称"公司"）的聘请，指派陈琳律师、向思律师（以下简称"本所律师"）出 ...

证券代码：000504 证券简称：南华生物 公告编号：2024-033 南华生物医药股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示: 1.本次股东大会存在否决提案的情形，未通过提案为：《关于使用闲置资金 进行委托理财暨关联交易的提案》； 2.本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （2）网络投票时间：2024年5月24日（星期五）。其中：通过深圳证券交易 所交易系统进行网络投票的具体时间为2024年5月24日9:15-9:25，9:30－11:30， 13:00-15:00；通过互联网投票系统进行网络投票的时间为2024年5月24日 9:15-15:00。 2.会议召开的地点：长沙高新开发区岳麓西大道1698号麓谷科技创新创业园 B1栋三层会议室 3.会议召开的方式：现场表决与网络投票相结合 4.会议召集人：公司第十一届董事会 5.会议主持人：董事长杨云先生 6.会议召开的合法合规性：本次股东大会会议召开符合《公司法》《证券法》 《上市公司股东大会规则》等法律、法规和 ...

的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、基本情况 南华生物医药股份有限公司（以下简称"公司"或"南华生物"）分别于2024 年4月8日、2024年4月24日召开了第十一届董事会第十九次会议、2024年第一次 临时股东大会，审议通过了修订《公司章程》及办理注册资本等变更登记的相关 议题，具体内容详见公司于2024年4月9日、2024年4月25日在巨潮资讯网 （www.cninfo.com.cn）披露的相关公告。 二、工商变更登记完成情况 公司已于近日完成了注册资本的工商变更及章程备案手续，并取得了湖南省 市场监督管理局换发的《营业执照》，具体登记信息如下： 证券代码：000504 证券简称：南华生物 公告编号：2024-032 南华生物医药股份有限公司 关于变更注册资本、修订《公司章程》暨完成工商变更登记 1.名称：南华生物医药股份有限公司； 2.注册资本：叁亿叁仟零贰万叁仟零玖拾捌元整； 3.类型：其他股份有限公司（上市）； 4.成立日期：1991年10月18日； 5.法定代表人：杨云； 6.住所：长沙市高新区岳麓西大道1698号麓谷科技 ...

（一）公司核查情况 针对公司股票交易异常波动，公司对有关事项进行了核查，对影响公司股票 异常波动的情况说明如下： 证券代码：000504 证券简称：南华生物 公告编号：2024-031 南华生物医药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动的情况介绍 南华生物医药股份有限公司（以下简称"公司"或"南华生物"）股票（证 券简称：南华生物，证券代码：000504）于2024年5月13日、2024年5月14日、2024 年5月15日连续三个交易日内收盘价格跌幅偏离值累计超过20%，根据《深圳证券 交易所交易规则》的有关规定，属于股票异常波动情形。 二、公司关注并核实情况 1.前期披露的信息不存在需要更正、补充之处； 2.近期公共传媒未出现报道了可能或已经对本公司股票交易价格产生较大 影响的未公开重大信息； 3.近期公司经营情况及内外部经营环境未发生重大变化； 4.不存在涉及要参照相关公告格式作出说明和披露的其他事项； 5.本公司不存在需要根据深交所《股票上市规则》等有关规定应予以披露而 未披露的事项； ...

南华生物医药股份有限公司 股票交易异常波动公告 证券代码：000504 证券简称：南华生物 公告编号：2024-030 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动的情况介绍 南华生物医药股份有限公司（以下简称"公司"或"南华生物"）股票（证 券简称：南华生物，证券代码：000504）于2024年5月7日、2024年5月8日、2024 年5月9日连续三个交易日内收盘价格涨幅偏离值累计超过20%，根据《深圳证券 交易所交易规则》的有关规定，属于股票异常波动情形。 二、公司关注并核实情况 （一）公司核查情况 针对公司股票交易异常波动，公司对有关事项进行了核查，对影响公司股票 异常波动的情况说明如下： 1.前期披露的信息不存在需要更正、补充之处； 2.近期公共传媒未出现报道了可能或已经对本公司股票交易价格产生较大 影响的未公开重大信息； 3.近期公司经营情况及内外部经营环境未发生重大变化； 4.不存在涉及要参照相关公告格式作出说明和披露的其他事项； 公司控股股东湖南省财信产业基金管理有限公司（以下简称"财信产业基 金"）、公司间接控股股东湖 ...

Financial Performance - The company's operating revenue for 2023 was CNY 136,790,924, representing a decrease of 31.72% compared to CNY 200,345,457 in 2022[24]. - The company has reported a significant decline in revenue, with a drop of approximately CNY 63,554,533 from the previous year[24]. - The net profit attributable to shareholders of the listed company for 2023 is ¥28,172,625.5, a decrease of 126.15% compared to the previous year[25]. - The operating income for 2023 is ¥136,790,924.97, down from ¥200,345,457.02 in 2022, representing a decline of approximately 31.6%[28]. - The net cash flow from operating activities for 2023 is ¥36,276,713.5, a significant decrease of 78.20% compared to the previous year[25]. - The total assets at the end of 2023 amount to ¥771,382,516, reflecting a 39.40% increase from ¥553,064,727 in 2022[25]. - The net assets attributable to shareholders of the listed company increased to ¥256,941,198, a substantial rise of 1,734.17% compared to ¥13,771,203.6 in 2022[25]. - The basic and diluted earnings per share for 2023 are both -¥0.09, indicating a 125.00% decline from -¥0.04 in 2022[25]. - The company reported a total of ¥14,253,206.95 in non-recurring gains and losses for 2023, compared to ¥8,899,505.35 in 2022[34]. - The company reported a total revenue of CNY 136.79 million in 2023, a decrease of 31.72% compared to CNY 200.35 million in 2022[61]. - The revenue from the biopharmaceutical segment was CNY 101.61 million, down 28.80% year-on-year, while the energy-saving and environmental protection segment generated CNY 34.97 million, a decline of 39.17%[62]. - The gross margin for the biopharmaceutical sector was 74.88%, while the energy-saving technology service sector had a gross margin of 48.06%[64]. Strategic Focus and Business Model - The company has shifted its main business focus from real estate and publishing to biomedicine and cell technology services since 2015[23]. - The company has undergone a strategic adjustment in its major shareholder structure, with the largest shareholder holding 25.58% of the total shares[23]. - The company has maintained its operational control under the Hunan Provincial Government despite changes in its shareholder structure[23]. - The company has developed a dual main business model of "biomedicine + energy-saving and environmental protection," with over 70 patents and software copyrights[57]. - The biopharmaceutical segment primarily provides cell medical services, including stem cell and immune cell storage and testing, in collaboration with hospitals and clinical research institutions[42]. - The company is focusing on the development of cutting-edge medical technologies such as vaccines, biotherapy, and precision medicine[40]. - The company aims to break through technological bottlenecks in high-end medical equipment and enhance its capabilities in cell therapy technologies[40]. - The company plans to strengthen the collaboration between production, learning, and research to accelerate the transformation and clinical application of related technologies[40]. Research and Development - R&D expenses increased by 25.86% to CNY 12,567,051.06, reflecting increased investment in research and development[75]. - The company has completed several R&D projects aimed at optimizing production processes and enhancing safety in stem cell preparation[76]. - The establishment of a serum-free culture system for umbilical cord mesenchymal stem cells has been completed, improving safety and production efficiency[76]. - The company is expanding its market share in the immune cell industry by developing NK cell storage technology[76]. - Ongoing research on the anti-aging effects of umbilical cord mesenchymal stem cells and NK cell exosomes is being conducted[76]. - The company has developed a new technology for the treatment of high-concentration liquor wastewater, achieving a total nitrogen removal rate of over 90%[79]. - The company has invested heavily in research and development for wastewater treatment technologies, establishing a proprietary intellectual property system[54]. Market and Industry Trends - The stem cell industry in China is expected to exceed 30 billion yuan by 2026, indicating significant market potential[37]. - The compound annual growth rate (CAGR) for China's environmental protection industry is projected to reach 12% from 2022 to 2027, with revenue expected to surpass 440 billion yuan by 2027[38]. - The total output value of China's energy-saving and environmental protection industry is anticipated to exceed 19 trillion yuan by 2027[38]. - The Chinese government has implemented multiple policies to support the development of the biopharmaceutical industry, particularly in stem cell and regenerative medicine[39]. - The regulatory framework for stem cell therapy in China is gradually being established, promoting industry growth[37]. Governance and Compliance - The company ensures strict compliance with information disclosure laws, providing timely and accurate information to shareholders[128]. - The company has established a complete and independent personnel system, ensuring that all employees are contracted directly with the company[133]. - The company has a dedicated financial department, ensuring independent financial decision-making and tax compliance[135]. - The company has committed to maintaining its independence and ensuring that its operations, assets, and financials remain distinct from any controlling parties[192]. - The internal control audit report received a standard unqualified opinion, reflecting the reliability of the company's financial practices[182]. Future Outlook and Guidance - The company aims to become a leading biotechnology company by focusing on high-quality development in stem cells and immune cells, while also making breakthroughs in medical device trade and skincare products in 2024[106]. - The company provided guidance for 2024, projecting a revenue growth of 10% to 1.32 billion yuan[139]. - New product launches are expected to contribute an additional 200 million yuan in revenue in 2024[139]. - The company plans to increase its marketing budget by 25% in 2024 to support new product launches and market penetration[139]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[199]. Risks and Challenges - The company faces a significant risk due to a declining birth rate in China, with rates of 7.52‰, 6.77‰, and 6.40‰ over the last three years[111]. - The company is exposed to regulatory and policy risks, as well as technology development risks, which could impact its operations if it fails to adapt to new regulations[112]. - Financial risks include fluctuations in gross margin and net profit, which could arise from changes in business income structure and operational performance[115]. - The competitive landscape in the energy-saving and environmental protection industry is intensifying, with many new entrants and increasing pressure from existing competitors[114].